FrancophonIA/ELRC3.0 huggingface dataset:
English: Arepanrix is a vaccine that is given by injection.
Estonian: Arepanrix on süstitav vaktsiin.
English: For more information about treatment with Arepanrix, read the Package Leaflet (also part of the EPAR).
Estonian: Ravimi kasutamise üksikasjalik teave on pakendi infolehel, mis on samuti Euroopa avaliku hindamisaruande osa.
English: 30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom day.
Estonian: 30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom
English: The maximum dose is 600 mg per
Estonian: Maksimaalne annus on 600 mg
English: Pregabalin Zentiva is available as capsules (25, 50, 75, 100, 150, 200, 225 and 300 mg) and can only be obtained with a prescription.
Estonian: Pregabalin Zentivat turustatakse kapslitena (25, 50, 75, 100, 150, 200, 225 ja 300 mg) ja see on retseptiravim.
English: Stopping treatment with Pregabalin Zentiva should also be done gradually, over at least a week.
Estonian: Ka ravi katkestamine Pregabalin Zentivaga peab toimuma järk-järgult, vähemalt ühe nädala jooksul.
English: The full EPAR and risk management plan summary for Pregabalin Zentiva can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Estonian: Euroopa avaliku hindamisaruande täistekst ja riskijuhtimiskava kokkuvõte Pregabalin Zentiva kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: A risk management plan has been developed to ensure that Pregabalin Zentiva is used as safely as possible.
Estonian: Töötati välja riskijuhtimiskava, et tagada Pregabalin Zentiva võimalikult ohutu kasutamine.
English: The European Commission granted a marketing authorisation valid throughout the European Union for Pregabalin Zentiva on 17 July 2015.
Estonian: Euroopa Komisjon andis Pregabalin Zentiva müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, 17. juulil 2015.
English: Pregabalin Zentiva pregabalin
Estonian: Pregabalin Zentiva pregabaliin
English: What measures are being taken to ensure the safe and effective use of Pregabalin Zentiva?
Estonian: Mis meetmed võetakse, et tagada Pregabalin Zentiva ohutu ja efektiivne kasutamine?
English: This reduces the activity of some of the nerve cells in the brain and spinal cord, reducing the release of other neurotransmitters that are involved in epilepsy and anxiety.
Estonian: See vähendab peaaju ja seljaaju närvirakkude elektrilist talitlust, vähendades nii teiste neurotransmitterite vabanemist, mis tekitavad epilepsiat ja ärevust.
English: The Committee recommended that Pregabalin Zentiva be approved for use in the EU.
Estonian: Komitee soovitas Pregabalin Zentiva kasutamise Euroopa Liidus heaks kiita.
English: What is Pregabalin Zentiva and what is it used for?
Estonian: Mis on Pregabalin Zentiva ja milleks seda kasutatakse?
English: This summary was last updated in July-2015.
Estonian: Kokkuvõtte viimane uuendus: 07-2015.
English: After three to seven days, the dose can be increased to 300 mg per day.
Estonian: Kolme kuni seitsme päeva möödudes võib ravimi ööpäevast annust suurendada 300 mg-ni. Annust võib suurendada kuni kaks korda efektiivseima annuse saavutamiseni.
English: The active substance in Pregabalin Zentiva, pregabalin, is similar in structure to the body's own ‘neurotransmitter' gamma‑amino butyric acid (GABA), but has very different biological effects.
Estonian: Pregabalin Zentiva toimeaine pregabaliin sarnaneb struktuurilt organismi loodusliku neurotransmitteri gamma-aminobutüürhappega (GABA), kuid on teistsuguse bioloogilise toimega.
English: Pregabalin Zentiva is a medicine used to treat adults with the following conditions:
Estonian: Pregabalin Zentiva on ravim, mida kasutatakse järgmiste haigusseisundite raviks täiskasvanutel:
English: Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Pregabalin Zentiva, including the appropriate precautions to be followed by healthcare professionals and patients.
Estonian: Selle alusel lisati Pregabalin Zentiva omaduste kokkuvõttesse ja pakendi infolehele ravimi ohutusteave, kus on ka tervishoiuspetsialistide ja patsientide võetavad meetmed.
English: Other information about Pregabalin Zentiva
Estonian: Muu teave Pregabalin Zentiva kohta
English: Because Pregabalin Zentiva is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine's.
Estonian: Et Pregabalin Zentiva on geneeriline ravim ja võrdlusravimiga bioekvivalentne, peetakse tema kasulikkust ja riske samadeks mis võrdlusravimil.
English: Pregabalin Zentiva is a ‘generic medicine'.
Estonian: Pregabalin Zentiva on geneeriline ravim.
English: It is not intended to provide practical advice on how to use Pregabalin Zentiva.
Estonian: Hindamisaruandes ei anta Pregabalin Zentiva kasutamise praktilisi nõuandeid.
English: This means that Pregabalin Zentiva is similar to a ‘reference medicine' already authorised in the European Union (EU) called Lyrica.
Estonian: See tähendab, et Pregabalin Zentiva on sarnane võrdlusravimiga Lyrica, millel juba on Euroopa Liidus müügiluba.
English: For practical information about using Pregabalin Zentiva, patients should read the package leaflet or contact their doctor or pharmacist.
Estonian: Kui vajate Pregabalin Zentiva kasutamise praktilisi nõuandeid, lugege pakendi infolehte või pöörduge oma arsti või apteekri poole.
English: Pregabalin Zentiva contains the active substance pregabalin.
Estonian: Pregabalin Zentiva sisaldab toimeainena pregabaliini.
English: This is a summary of the European public assessment report (EPAR) for Pregabalin Zentiva.
Estonian: See on ravimi Pregabalin Zentiva Euroopa avaliku hindamisaruande kokkuvõte.
English: The Agency's Committee for Medicinal Products for Human Use (CHMP) concluded that, in accordance with EU requirements, Pregabalin Zentiva has been shown to have comparable quality and to be bioequivalent to Lyrica.
Estonian: Inimravimite komitee järeldas, et vastavalt Euroopa Liidu nõuetele on tõendatud ravimi Pregabalin Zentiva võrreldav kvaliteet ja bioekvivalentsus ravimiga Lyrica.
English: Therefore, the CHMP's view was that, as for Lyrica, the benefit outweighs the identified risk.
Estonian: Seetõttu on inimravimite komitee arvamusel, et nagu ka Lyrica korral, ületab ravimi Pregabalin Zentiva kasulikkus sellega kaasnevad riskid.
English: Why is Pregabalin Zentiva approved?
Estonian: Miks Pregabalin Zentiva heaks kiideti?
English: For more information about treatment with Pregabalin Zentiva, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate Pregabalin Zentivaga toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: Because Pregabalin Zentiva is a generic medicine, studies in people have been limited to tests to determine that it is bioequivalent to the reference medicine, Lyrica.
Estonian: Et Pregabalin Zentiva on geneeriline ravim, piirdusid patsiendiuuringud katsetega, milles näidati Pregabalin Zentiva bioekvivalentsust võrdlusravimiga Lyrica.
English: • epilepsy, where it is used as an ‘add-on' to existing treatment in patients who have partial seizures
Estonian: • epilepsia, mille korral seda ravimit kasutatakse lisaks olemasolevale ravile patsientidel, kelle partsiaalsed krambid (aju teatud osas algavad epilepsiahood) ei ole allunud senisele ravile;
English: How is Pregabalin Zentiva used?
Estonian: Kuidas Pregabalin Zentivat kasutatakse?
English: How has Pregabalin Zentiva been studied?
Estonian: Kuidas Pregabalin Zentivat uuriti?
English: What are the benefits and risks of Pregabalin Zentiva?
Estonian: Milles seisneb Pregabalin Zentiva kasulikkus ja mis riskid ravimiga kaasnevad?
English: How does Pregabalin Zentiva work?
Estonian: Kuidas Pregabalin Zentiva toimib?
English: CONCLUSIONS ON <SIMILARITY AND DEROGATION> <AND> < THE REQUEST FOR ONE-YEAR <MARKETING PROTECTION> <DATA EXCLUSIVITY>> PRESENTED BY THE EUROPEAN MEDICINES AGENCY
Estonian: EUROOPA RAVIMIAMETI ESITATUD JÄRELDUSED <SARNASUSE JA ERANDI> <JA> <ÜHE AASTA PIKKUSE <MÜÜGIKAITSE> <ANDMETE AINUÕIGUSE PERIOODI> TAOTLUSE> KOHTA
English: <the applicant could establish in the application that the medicinal product, although similar to <authorised orphan medicinal product>, is safer, more effective or otherwise clinically superior (as defined in Article 3 of Commission Regulation (EC) No. 847/2000) for the same therapeutic indication>.
Estonian: <taotleja suutis taotluses tõestada, et ravim, kuigi <müügiloa saanud harvikravimiga> sarnane, on samal näidustusel ohutum, efektiivsem või muul viisil kliiniliselt parem (komisjoni määruse (EÜ) nr 847/2000 artiklis 3 esitatud määratluse järgi)> <ja>
English: [Art 74(a)- legal status switch]<Furthermore, the CHMP reviewed the data submitted by the Marketing Authorisation Holder, taking into account the provisions of Article 74(a) of Directive 2001/83/EC, and considers that the data submitted in support of the classification of {specify medicinal product name} as ‘medicinal product not subject to medical prescription' were significant as further explained in the European Public Assessment Report.>
Estonian: [Art 74(a)- legal status switch]<Inimravimite komitee vaatas direktiivi 2001/83/EÜ artikli 74a sätteid arvesse võttes läbi müügiloa hoidja esitatud andmed ning leiab, et ravimi {nimetus} „käsimüügiravimina˝ liigitamise toetuseks esitati olulisi andmeid, nagu on kirjeldatud Euroopa avalikus hindamisaruandes.>
English: Efficacy results are summarized in Table 5.
Estonian: Efektiivsuse tulemused on kokku võetud tabelis 5.
English: and ≥ 10%
Estonian: ja ≥ 10%
English: Once the dose has been reduced, it should not be increased at a later time.
Estonian: Kui annust on kord vähendatud, ei tohi seda enam hiljem suurendada.
English: N/A = Not Applicable
Estonian: N/A = ei ole asjakohane
English: MARKETING AUTHORISATION NUMBER(S) EU/1/15/1048/001
Estonian: MÜÜGILOA NUMBER (NUMBRID) EU/1/15/1048/001
English: Study NO25395 (BRIM7)
Estonian: Uuring NO25395 (BRIM7)
English: (or 40-49%
Estonian: (või 40...49%
English: How much to take
Estonian: Kui palju ravimit tuleb võtta
English: Fatigue was observed at similar frequencies in both arms.
Estonian: Väsimust täheldati mõlemas rühmas sarnase sagedusega.
English: · Take the tablets every day for 21 days (called a “treatment period”).
Estonian: • Võtke tablette iga päev 21 päeva jooksul (seda nimetatakse „raviperioodiks“).
English: DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION 20 November 2015
Estonian: ESMASE MÜÜGILOA VÄLJASTAMISE/MÜÜGILOA UUENDAMISE KUUPÄEV 20. november 2015
English: Grade (CTC-AE)*
Estonian: Raskusaste (CTC-AE)*
English: Cotellic with food and drink
Estonian: Cotellic koos toidu ja joogiga
English: Transparent PVC/PVDC blisters containing 21 tablets.
Estonian: Läbipaistvad PVC/PVDC blistrid, mis sisaldavad 21 tabletti.
English: Follow your doctor's instructions for what to do to help prevent or treat diarrhoea.
Estonian: Järgige oma arsti juhiseid selle kohta, mida teha kõhulahtisuse ennetamiseks või ravimiseks.
English: Changes in reported laboratory data
Estonian: Kirjeldatud laboratoorsete andmete muutused
English: Cotellic is taken on a 28 day cycle.
Estonian: Cotellic'ut võetakse 28-päevase tsüklina.
English: Study GO28141 (coBRIM)
Estonian: Uuring GO28141 (coBRIM)
English: These data show that the efficacy of the combination will be lower in these patients (see section 5.1).
Estonian: Need andmed näitavad, et nimetatud patsientidel on kombinatsiooni efektiivsus väiksem (vt lõik 5.1).
English: The difference in ORR was 22.9 % (p-value<0.0001).
Estonian: ORR-i erinevus oli 22,9% (p-väärtus < 0,0001).
English: On average, 94% of the dose was recovered within 17 days.
Estonian: Keskmiselt 94% annusest eritus 17 päeva jooksul.
English: Take the medicine package and this leaflet with you.
Estonian: Võtke ravimi pakend ja käesolev infoleht endaga kaasa.
English: Mortality occurred in juvenile animals at a dose (3 mg/kg) which did not lead to mortalities in adult animals.
Estonian: Surma põhjustas noortel loomadel annus (3 mg/kg), mis ei põhjustanud surma täiskasvanud loomadel.
English: 0.70 (95% CI: 0.55, 0.90) (p-value = 0.0050
Estonian: 0,70 (95% CI: 0,55; 0,90) (p-väärtus = 0,0050
English: Interrupt treatment for 4 weeks
Estonian: Katkestada ravi 4 nädalaks
English: Interrupt treatment for 2 weeks
Estonian: Katkestada ravi 2 nädalaks
English: The majority of events were Grade 1 or 2 and non-serious.
Estonian: Enamik olid 1. või 2. raskusastme mittetõsised juhud.
English: Malta (see Ireland)
Estonian: Malta (see United Kingdom )
English: Primary Endpoint a, f
Estonian: Esmane tulemusnäitaja a, f
English: The decision on whether to reduce the dose for either or both treatments should be based on the prescriber's assessment of individual patient safety or tolerability.
Estonian: Otsus, kas vähendada ühe või mõlema ravimi annust, peab põhinema arsti poolt patsiendi ohutusele või taluvusele antud individuaalsel hinnangul.
English: Continue to take Cotellic as normal, the next day.
Estonian: Jätkake Cotellic'u võtmist nagu tavaliselt järgmisel päeval.
English: Symptomatic regardless of LVEF Permanent discontinuation
Estonian: Sümptomaatiline hoolimata LVEF-ist Ravi püsiv lõpetamine
English: If you are sick
Estonian: Kui te oksendate
English: No oxidative metabolites greater than 10% of total circulating radioactivity or human specific metabolites were observed in plasma.
Estonian: Plasmas ei täheldatud oksüdatiivseid metaboliite enam kui 10% ulatuses kogu ringlevast radioaktiivsusest ega inimesele spetsiifilisi metaboliite.
English: Other medicines and Cotellic
Estonian: Muud ravimid ja Cotellic
English: Treatment with Cotellic should continue until the patient no longer derives benefit or until the development of unacceptable toxicity (see Table 1 below).
Estonian: Ravi Cotellic'uga peab jätkuma seni, kuni patsient ei saa enam ravist kasu või kuni vastuvõetamatu toksilisuse tekkimiseni (vt tabel 1 allpool).
English: Then take the next dose at the usual time.
Estonian: Võtke järgmine annus tavalisel ajal.
English: LVEF value
Estonian: LVEF väärtus
English: Since food does not alter the pharmacokinetics of cobimetinib, it can be administered with or without food.
Estonian: Kuna toit ei muuda kobimetiniibi farmakokineetikat, võib seda manustada koos toiduga või ilma.
English: The following convention has been used for the classification of frequency:
Estonian: Kõrvaltoimed on rühmitatud esinemissageduse klassifikatsiooni järgi:
English: g The data cut-off date for the final OS analysis is 28 August 2015 and median follow-up was 18.5 months.
Estonian: Lõpliku OS-i analüüsi andmete kuupäev on 28. august 2015 ja järelkontrolli mediaan oli 18,5 kuud.
English: Before starting treatment, your doctor will test for this mutation.
Estonian: Enne ravi alustamist testib arst teid selle mutatsiooni suhtes.
English: (or 40-49% and < 10% absolute decrease from baseline)
Estonian: (või 40...49% ja < 10% absoluutne langus võrreldes ravieelsega)
English: One pack size is available: 63 tablets (3 blisters of 21 tablets).
Estonian: Saadaval on üks pakendi suurus: 63 tabletti (kolm 21 tabletiga blistrit).
English: Your doctor will do blood tests to monitor for this.
Estonian: Arst teeb vereanalüüsid selle kontrollimiseks.
English: · Do not throw away any medicines via wastewater or household waste.
Estonian: • Ärge visake ravimeid kanalisatsiooni ega olmejäätmete hulka.
English: Each pack contains 63 tablets.
Estonian: Üks pakend sisaldab 63 tabletti.
English: Treatment should be taken for 21 consecutive days followed by a 7-day break
Estonian: Ravimit tuleb võtta 21 järjestikusel päeval, millele järgneb 7-päevane paus
English: Patients should be advised not to drive or use machines if they experience visual disturbances or any other adverse effects that may affect their ability.
Estonian: Patsiente tuleb teavitada, et nad ei juhiks autot ega töötaks masinatega, kui esinevad nägemishäired või muud kõrvaltoimed, mis võivad seda mõjutada.
English: · After the 21 days, do not take any Cotellic tablets for 7 days.
Estonian: • Pärast 21 päeva möödumist ärge võtke Cotellic'u tablette 7 päeva jooksul.
English: Some of these eye problems may be a result of “serous retinopathy” (a build-up of fluid under the retina in the eye).
Estonian: Mõned nendest silmaprobleemidest võivad tekkida „seroosse retinopaatia“ (vedeliku kogunemine silma võrkkesta alla) tagajärjel.
English: · Periodic safety update reports
Estonian: • Perioodilised ohutusaruanded
English: The mean steady-state Cmax and AUC0-24 were 273 ng/mL and 4340 ng.h/mL respectively.
Estonian: Keskmised tasakaaluseisundi Cmax ja AUC0-24 väärtused olid vastavalt 273 ng/ml ja 4340 ng.h/ml.
English: The tablets contain lactose (a type of sugar).
Estonian: Tabletid sisaldavad laktoosi (teatud tüüpi suhkur).
English: It is important to keep taking Cotellic for as long as your doctor prescribes it.
Estonian: Tähtis on jätkata Cotellic'u võtmist senikaua, kui arst seda soovitab.
English: The clinical relevance of this is unknown.
Estonian: Selle kliiniline tähtsus on teadmata.
English: · At the request of the European Medicines Agency; · Whenever the risk management system is modified, especially as the result of new information being received that may lead to a significant change to the benefit/risk profile or as the result of an important (pharmacovigilance or risk minimisation) milestone being reached.
Estonian: • kui muudetakse riskijuhtimissüsteemi, eriti kui saadakse uut teavet, mis võib oluliselt mõjutada riski/kasu suhet, või kui saavutatakse oluline (ravimiohutuse või riski minimeerimise) eesmärk.
English: Pharmacotherapeutic group: Antineoplastic agents, ATC code: L01XE38
Estonian: Farmakoterapeutiline rühm: kasvajavastased ained, ATC-kood: L01XE38
English: In case of vomiting after administration of Cotellic, the patient should not take an additional dose on that day and treatment should be continued as prescribed the following day.
Estonian: Oksendamise korral pärast Cotellic'u manustamist ei tohi patsient samal päeval võtta ravimi lisaannust ning ravi tuleb jätkata nagu ette nähtud järgmisel päeval.
English: The safety and efficacy of Cotellic in children and adolescents below 18 years of age have not been established.
Estonian: Cotellic'u ohutus ja efektiivsus lastel ja noorukitel vanuses alla 18 aasta ei ole tõestatud.
English: · Cotellic is not recommended during pregnancy - although the effects of Cotellic have not been studied in pregnant women, it may cause permanent harm or birth defects to an unborn baby.
Estonian: • Cotellic'ut ei ole soovitatav kasutada raseduse ajal - kuigi rasedatel ei ole Cotellic'u toimeid uuritud, võib see püsivalt kahjustada veel sündimata last (sünnidefektid).
English: If doses are omitted for toxicity, these doses should not be replaced.
Estonian: Kui annused jäävad vahele toksilisuse tõttu, siis neid annuseid ei asendata.
English: · Cotellic can be taken with or without food.
Estonian: • Cotellic'ut võib võtta koos toiduga või ilma.
English: The intracranial activity of cobimetinib is currently unknown (see sections 5.1 and 5.2).
Estonian: Kobimetiniibi koljusisene toime on praegu teadmata (vt lõigud 5.1 ja 5.2).
English: The median follow up was 14.2 months.
Estonian: Järelkontrolli mediaan oli 14,2 kuud.
English: Tell your doctor straight away if you get diarrhoea.
Estonian: Teavitage oma arsti otsekohe sellest, kui teil tekib kõhulahtisus.
English: Among patients who had progressed on vemurafenib (n=66), the objective response rate was 15%.
Estonian: Patsientide seas, kelle haigus oli vemurafeniibravi ajal progresseerunud (n=66), oli objektiivse ravivastuse määr 15%.
English: Cotellic contain lactose
Estonian: Cotellic sisaldab laktoosi
English: Your doctor should do tests before and during your treatment with Cotellic to check how well your heart can pump blood.
Estonian: Arst teeb enne ravi ja ravi ajal Cotellic'uga teile uuringud, et kontrollida, kui hästi suudab teie süda verd pumbata.
English: A decision should be made whether to discontinue breast-feeding or discontinue Cotellic therapy, taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman.
Estonian: Tuleb otsustada, kas lõpetada rinnaga toitmine või ravi Cotellic'uga, võttes arvesse imetamisest saadavat kasu lapsele ja ravist saadavat kasu naisele.
English: Also, some other medicines can affect the way Cotellic works.
Estonian: Samuti võivad mõned teised ravimid mõjutada Cotellic'u toimet.
English: · It is used in combination with another anti-cancer medicine called vemurafenib.
Estonian: • Seda kasutatakse koos teise vähivastase ravimiga, mida nimetatakse vemurafeniibiks.
English: All patients restarting treatment with a dose reduction of Cotellic should have LVEF measurements taken after approximately 2 weeks, 4 weeks, 10 weeks and 16 weeks, and then as clinically indicated.
Estonian: Kõikidele patsientidele, kes alustavad uuesti ravi Cotellic'u vähendatud annusega, tuleb LVEF mõõtmised teha ligikaudu 2 nädala, 4 nädala, 10 nädala ja 16 nädala möödudes ning seejärel nagu kliiniliselt näidustatud.
English: When Cotellic is used in combination with vemurafenib (which targets the changed “BRAF” protein), it further slows down or stops the growth of your cancer.
Estonian: Kui Cotellic'ut kasutatakse kombinatsioonis vemurafeniibiga (mis on suunatud muutunud „BRAF“-valgu vastu), aeglustab see veelgi või peatab vähi kasvu.
English: Cotellic should not be used during pregnancy unless clearly necessary and after a careful consideration of the needs of the mother and the risk to the foetus.
Estonian: Cotellic'ut tohib raseduse ajal kasutada ainult selge vajaduse korral ning pärast ema vajaduste ja lootele kaasneva riski hoolikat hindamist.
English: LVEF value following treatment break
Estonian: LVEF väärtus pärast ravipausi
English: The clinical relevance of these findings has not been investigated.
Estonian: Nende leidude kliinilist tähtsust ei ole uuritud.
English: The BRAFi-naïve patients (n=63) attained an 87% objective response rate, including a complete response in 16% of patients.
Estonian: Varem BRAFi-ravi mittesaanud patsiendid (n=63) saavutasid 87% objektiivse ravivastuse määra, sealhulgas täieliku ravivastuse saavutas 16% patsientidest.
English: Oxidation by CYP3A and glucuronidation by UGT2B7 appear to be the major pathways of cobimetinib metabolism.
Estonian: Oksüdatsioon CYP3A ja glükuronisatsioon UGT2B7 vahendusel näivad olevat põhilised kobimetiniibi metabolismi rajad.
English: Film coating Polyvinyl alcohol Titanium dioxide (E171) Macrogol 3350
Estonian: Tableti kate Polüvinüülalkohol Titaandioksiid (E171) Makrogool 3350
English: Lactose monohydrate Microcrystalline cellulose (E460) Croscarmellose sodium (E468) Magnesium stearate (E470b)
Estonian: Laktoosmonohüdraat Mikrokristalliline tselluloos (E460) Naatriumkroskarmelloos (E468) Magneesiumstearaat (E470b)
English: No preferential binding to human red blood cells was observed (blood to plasma ratio 0.93).
Estonian: Eelistatud seondumist inimese erütrotsüütidega ei täheldatud (vere/plasma suhe 0,93).
English: · Do not take this medicine after the expiry date which is stated on the blister and the carton after EXP.
Estonian: • Ärge kasutage seda ravimit pärast kõlblikkusaega, mis on märgitud blistril ja karbil pärast
English: Cotellic is used to treat adult patients with a type of skin cancer called melanoma, that has spread to other parts of the body or cannot be removed by surgery.
Estonian: Cotellic'ut kasutatakse täiskasvanud patsientidel melanoomiks nimetatud nahavähi raviks, mis on levinud teistesse kehaosadesse või mida ei saa eemaldada operatsiooni teel.
English: Table 4 Liver function and other laboratory tests observed in the Phase III Study GO28141
Estonian: Tabel 4 Maksafunktsiooni ja muud laboratoorsed kõrvalekalded, mida täheldati III faasi uuringus GO28141